The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia: A 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Open accessAbstract
OBJECTIVE: To evaluate the efficacy and tolerability of a once-monthly intramuscular (IM) depot formulation of the dopamine partial agonist aripiprazole as maintenance treatment in adults meeting DSM-IV-TR schizophrenia criteria. METHOD: The study was conducted from July 2008 until February 2011. Subjects requiring chronic treatment with an antipsychotic entered a 4- to 12-week oral stabilization phase and received oral aripiprazole (10-30 mg/d). Subjects meeting stability criteria for 4 weeks entered an IM-depot stabilization phase in which they received 400-mg aripiprazole-IM-depot injections every 4 weeks (single decrease to 300 mg permitted) with coadministration of oral aripiprazole tablets in the first 2 weeks. Subjects meeting stability criteria for 12 consecutive weeks were randomly assigned (2:1) to aripiprazole-IM-depot or placebo during a 52-week, double-blind maintenance phase. The primary outcome measure was time to exacerbation of psychotic symptoms/impending relapse (event). Safety and tolerability were also assessed. RESULTS: 710 patients entered oral stabilization, 576 progressed to IM-depot stabilization, and 403 were randomly assigned to double-blind treatment. The study was terminated early because efficacy was demonstrated by the preplanned interim analysis (conducted after 64 events). Time to impending relapse was significantly delayed with aripiprazole-IM-depot treatment compared with placebo in both the interim analysis and the final analysis (P < .0001, log-rank test). The hazard ratio (placebo/aripiprazole-IM-depot) at final analysis was 5.03 (95% CI, 3.15-8.02). The rate of impending relapse was significantly lower with aripiprazole-IM-depot than placebo at endpoint (final analysis, 10.0% [n = 27/269] vs 39.6% [n = 53/134]). Improvements in Clinical Global Impressions-Severity of Illness scale and Positive and Negative Syndrome Scale total scores were maintained with aripiprazole-IM-depot treatment but showed significant worsening with placebo (change from double-blind baseline, P < .0001 for aripiprazole-IM-depot vs placebo). The most common treatment-emergent adverse events (occurring in ≥ 5% of aripiprazole-IM-depot subjects and greater than placebo) were insomnia, tremor, and headache. CONCLUSIONS: Aripiprazole-IM-depot significantly delayed time to impending relapse compared with placebo and appears to be a well-tolerated maintenance treatment option for schizophrenia. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00705783.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
(1976) · Medical Entomology and Zoology · Cited by 8,899
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Burris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619
Gilmer, T. P., Dolder, C. R., Lacro, J. P., Folsom, D. P., Lindamer, L., Garcia, P., & Jeste, D. V. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.692 · Cited by 603
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
Jordan, S., Koprivica, V., Chen, R., Tottori, K., Kikuchi, T., & Altar, C. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01532-7 · Cited by 512
Ascher-Svanum, H., Faries, D. E., Zhu, B., Ernst, F. R., Swartz, M. S., & Swanson, J. W. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0317 · Cited by 485
Cited by
Maintenance treatment with antipsychotic drugs for schizophrenia
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., & Davis, J. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008016.pub2 · Cited by 290
Calabrese, J. R., Sanchez, R., Jin, N., Amatniek, J., Cox, K., Johnson, B., Perry, P., Hertel, P., Such, P., Salzman, P. M., et al. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m11201 · Cited by 135
Self-citationFleischhacker, W. W., Hobart, M., Ouyang, J., Forbes, A., Pfister, S., McQuade, R. D., Carson, W. H., Sanchez, R., Nyilas, M., & Weiller, E. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw076 · Cited by 88
Self-citationAboraya, A., & Nasrallah, H. A. (2016) · Annals of Clinical Psychiatry · doi:10.1177/104012371602800206 · Cited by 46
Using behavioral rhythms and multi-task learning to predict fine-grained symptoms of schizophrenia
Tseng, V. W.-S., Sano, A., Ben-Zeev, D., Brian, R., Campbell, A. T., Hauser, M., Kane, J. M., Scherer, E. A., Wang, R., Wang, W., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71689-1 · Cited by 44
Self-citation
Metadata
- Authors
- Kane, J. M., Sanchez, R., Perry, P. P., Jin, N., Johnson, B. R., Forbes, R. A., McQuade, R. D., Carson, W. H., & Fleischhacker, W. W.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2012-05-15
- Volume
- 73
- Issue
- 05
- Pages
- 617-624
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2037650878
- Cited by
- 361
- References
- 30
- FWCI
- 12.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia: A 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. https://app.cochat.ai/papers/10.4088/jcp.11m07530
- The paper
- Kane, J. M., Sanchez, R., Perry, P. P., Jin, N., Johnson, B. R., Forbes, R. A., McQuade, R. D., Carson, W. H., & Fleischhacker, W. W. (2012). Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia: A 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.11m07530
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.